International Assets Investment Management LLC Acquires 186,271 Shares of Kenvue Inc. (NYSE:KVUE)

International Assets Investment Management LLC increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1,748.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 196,927 shares of the company’s stock after buying an additional 186,271 shares during the quarter. International Assets Investment Management LLC’s holdings in Kenvue were worth $4,240,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. purchased a new position in Kenvue in the third quarter valued at about $2,944,816,000. FMR LLC increased its position in Kenvue by 572.1% in the third quarter. FMR LLC now owns 89,182,980 shares of the company’s stock worth $1,790,794,000 after buying an additional 75,913,107 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Kenvue by 576.1% in the third quarter. Wellington Management Group LLP now owns 71,686,830 shares of the company’s stock valued at $1,439,472,000 after buying an additional 61,084,123 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Kenvue by 227.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 61,091,189 shares of the company’s stock valued at $1,226,711,000 after buying an additional 42,449,470 shares during the last quarter. Finally, Morgan Stanley grew its stake in shares of Kenvue by 4,057.4% during the 3rd quarter. Morgan Stanley now owns 31,162,614 shares of the company’s stock worth $625,745,000 after acquiring an additional 30,413,040 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE opened at $20.45 on Thursday. Kenvue Inc. has a 12-month low of $17.82 and a 12-month high of $27.80. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The stock has a 50-day moving average price of $19.87 and a 200-day moving average price of $20.12.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $3.79 billion. Kenvue’s quarterly revenue was down 24.9% compared to the same quarter last year. Equities analysts expect that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be given a dividend of $0.20 per share. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 3.91%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. William Blair started coverage on shares of Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating on the stock. Royal Bank of Canada reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. Sanford C. Bernstein assumed coverage on Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. HSBC lifted their price target on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a research report on Wednesday. Finally, The Goldman Sachs Group started coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $24.38.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.